Verónica Llauró
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Verónica Llauró has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alexis Aceituno
Subdepartamento de Registro Sanitario de Productos Farmacéuticos Bioequivalentes, Agencia Nacional de Medicamentos, Instituto de Salud Pública, Santiago 7780050, Chile
1 shared publication - Claudia Miranda
Unit of Modeling & Experimental Biopharmaceutics, Central “Marta Abreu” de Las Villas, Centro de Bioactivos Químicos Universidad, Santa Clara 50100, Cuba
1 shared publication - Gustavo Mendes Lima Santos
General Office of Medicines and Biological Products, Brazilian Health Regulatory Agency, 71205-050 Brasilia, DF, Brazil
1 shared publication - Miguel Ángel Cabrera-Pérez
General Directorate to Combat Climate Change and the Environment, Biodiversity Service, Canary Islands Government, Plaza de los Derechos Humanos, 22, Edificio Servicios Múltiples I. 8ª Planta, 35071 Las Palmas de Gran Canaria, Spain
1 shared publication - Mirna Fernández
Instituto de Farmacia y Alimentos. Universidad de La Habana
1 shared publication - Yanina Rodríguez
Laboratorio Nacional de Control, Dirección de Fiscalización y Gestión de Riesgo, Administración Nacional de Medicamentos, Alimentos y Tecnología Médica, C1084AAD Buenos Aires, Argentina
1 shared publication
Latest Publications
- Open Access
- 10 March 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (3) , 363
ICH Guideline for Biopharmaceutics Classification System-Based Biowaiver (M9): Toward Harmonization in Latin American Countries
The biopharmaceutical classification system (BCS) is a very important tool to replace the traditional in vivo bioequivalence studies with in vitro dissolution assays during multisource product development. This paper compares the most recent harmonized guideline for biowaivers based on the biopharmaceutics classification system and the BCS regulatory guidelines in Latin America and analyzes the current BCS regulatory requirements and the perspective of the harmonization in the region to develop safe and effective multisource products. Differences and similarities between the official and publicly available BCS guidelines of several Latin American regulatory authorities and the new ICH harmonization guideline were identified and compared. Only Chile, Brazil, Colombia, and Argentina have a more comprehensive BCS guideline, which includes solubility, permeability, and dissolution requirements. Although their regulatory documents have many similarities with the ICH guidelines, there are still major differences in their interpretation and application. This situation is an obstacle to the successful development of safe and effective multisource products in the Latin American region, not only to improve their access to patients at a reasonable cost, but also to develop BCS biowaiver studies that fulfill the quality standards of regulators in developed and emerging markets.
- 10 March 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (3) , 363
Open AccessICH Guideline for Biopharmaceutics Classification System-Based Biowaiver (M9): Toward Harmonization in Latin American Countries
The biopharmaceutical classification system (BCS) is a very important tool to replace the traditional in vivo bioequivalence studies with in vitro dissolution assays during multisource product development. This paper compares the most recent harmonized guideline for biowaivers based on the biopharmaceutics classification system and the BCS regulatory guidelines in Latin America and analyzes the current BCS regulatory requirements and the perspective of the harmonization in the region to develop safe and effective multisource products. Differences and similarities between the official and publicly available BCS guidelines of several Latin American regulatory authorities and the new ICH harmonization guideline were identified and compared. Only Chile, Brazil, Colombia, and Argentina have a more comprehensive BCS guideline, which includes solubility, permeability, and dissolution requirements. Although their regulatory documents have many similarities with the ICH guidelines, there are still major differences in their interpretation and application. This situation is an obstacle to the successful development of safe and effective multisource products in the Latin American region, not only to improve their access to patients at a reasonable cost, but also to develop BCS biowaiver studies that fulfill the quality standards of regulators in developed and emerging markets.